Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
Clinical Data ASCO: Summit reached with China lung data but new climb begins to prove global benefit pharminent June 1, 2026
Regulatory FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy pharminent June 1, 2026
Clinical Data Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers pharminent May 29, 2026
Regulatory Replimune gives cancer immunotherapy a third try after FDA leadership shakeup pharminent May 29, 2026
M&A / Deals Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent pharminent May 29, 2026
Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
Clinical Data Merck ADC, licensed from China, hits mark in first big global trial pharminent May 18, 2026
Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies pharminent May 18, 2026
Regulatory FDA approves Enhertu for two HER2-positive early breast cancer indications pharminent May 18, 2026
Regulatory Regulatory round-up: A month of key FDA approvals for cancer drugs pharminent May 14, 2026
M&A / Deals Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion pharminent May 12, 2026
Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026
M&A / Deals UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies pharminent May 7, 2026
Clinical Data Celcuity strengthens case for ASCO-spotlighted breast cancer drug pharminent May 4, 2026
Clinical Data Summit shares descend as PD-1/VEGF asset misses early survival mark pharminent May 4, 2026
Pipeline AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio pharminent April 30, 2026
M&A / Deals AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B pharminent April 28, 2026
Clinical Data AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer pharminent April 28, 2026
Regulatory Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA pharminent April 27, 2026
Pipeline Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer pharminent April 24, 2026
Commercial Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs pharminent April 23, 2026
